ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

ChemoCentryx, a biopharmaceutical company, announced that CEO Thomas J. Schall will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 5:00 p.m. ET. A live audio webcast of the event will be accessible on the company’s website, with a replay available for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory and autoimmune diseases, notably through its lead candidate, avacopan (CCX168), which is in late-stage clinical development for several conditions.

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET.

A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When is the ChemoCentryx fireside chat?

The ChemoCentryx fireside chat will take place on August 11, 2021, at 5:00 p.m. ET.

Where can I access the ChemoCentryx presentation?

The presentation can be accessed live via the Investors section of ChemoCentryx's website.

What is ChemoCentryx's lead drug candidate?

ChemoCentryx's lead drug candidate is avacopan (CCX168), which is in late-stage clinical development.

What conditions is avacopan being developed for?

Avacopan is being developed for ANCA-associated vasculitis, severe Hidradenitis Suppurativa, and C3 glomerulopathy.

How long will the webcast replay be available?

The replay of the webcast will be available for two weeks following the live presentation.